Scholarlink

Purpose <p>This study investigated the effects of Nintedanib, a triple tyrosine kinase inhibitor, on cavernosal tissues in a rat model of ischemic priapism (IP), focusing on fibrosis and erectile function.</p> Methods <p>Sixty male Wistar Albino rats were divided into five groups (<i>n</i> = 12): Group 1 (control), Group 2 (1-hour IP + penectomy), Group 3 (1-hour IP + 6-week follow-up), Group 4 (1-hour IP + Nintedanib treatment for 6 weeks), and Group 5 (Nintedanib only). Erectile function was evaluated via intracavernosal pressure (ICP) during nerve stimulation. Fibrosis was assessed using Masson’s trichrome staining and immunohistochemistry for VEGFR-2, PDGFR-β, and FGF-1. Oxidative stress markers (MDA, GSH, SOD) and growth factors were analyzed via ELISA and spectrophotometry. Statistical analysis used Kruskal-Wallis and Mann-Whitney U tests (<i>p</i> &lt; 0.05).</p> Results <p>Group 4 had significantly lower mean intracavernosal pressure (MeICP) values (median 26.5 mmHg) than Group 3 (49 mmHg) (<i>p</i> &lt; 0.001). Masson’s trichrome showed highest fibrosis in Group 4 (score 3 [2–4]) compared to Group 3 (score 3 [1–4]) (<i>p</i> &lt; 0.001). VEGFR-2 ELISA levels dropped in Group 4 (6.55 ng/mL [5.5–7.1]) vs. Group 3 (7.75 ng/mL [7–7.9]) (<i>p</i> &lt; 0.001). MDA levels peaked in Group 4 (33.66 nmol/g [24.39–45.39]), while GSH values remained comparable between Groups 3 and 4. SOD increased significantly in Groups 2–4 (Group 4: 6.25 ng/mL [5.2–7.0]) compared to Group 1 (4.95 ng/mL [3.9–5.6]) (<i>p</i> &lt; 0.001).</p> Conclusion <p>Although Nintedanib is antifibrotic in pulmonary contexts, it appears to promote penile fibrosis post-IP, likely via excessive VEGFR-2 inhibition, impairing vascular recovery and erectile function. Further studies are needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of antifibrotic agent Nintedanib on experimentally generated priapism model in rats

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月21日

查看全文
  • Gökhan Çeker,
  • Reha Girgin,
  • Onder Cinar,
  • Esin Kaymaz,
  • Salih Erdem,
  • Inci Turan

摘要

Purpose

This study investigated the effects of Nintedanib, a triple tyrosine kinase inhibitor, on cavernosal tissues in a rat model of ischemic priapism (IP), focusing on fibrosis and erectile function.

Methods

Sixty male Wistar Albino rats were divided into five groups (n = 12): Group 1 (control), Group 2 (1-hour IP + penectomy), Group 3 (1-hour IP + 6-week follow-up), Group 4 (1-hour IP + Nintedanib treatment for 6 weeks), and Group 5 (Nintedanib only). Erectile function was evaluated via intracavernosal pressure (ICP) during nerve stimulation. Fibrosis was assessed using Masson’s trichrome staining and immunohistochemistry for VEGFR-2, PDGFR-β, and FGF-1. Oxidative stress markers (MDA, GSH, SOD) and growth factors were analyzed via ELISA and spectrophotometry. Statistical analysis used Kruskal-Wallis and Mann-Whitney U tests (p < 0.05).

Results

Group 4 had significantly lower mean intracavernosal pressure (MeICP) values (median 26.5 mmHg) than Group 3 (49 mmHg) (p < 0.001). Masson’s trichrome showed highest fibrosis in Group 4 (score 3 [2–4]) compared to Group 3 (score 3 [1–4]) (p < 0.001). VEGFR-2 ELISA levels dropped in Group 4 (6.55 ng/mL [5.5–7.1]) vs. Group 3 (7.75 ng/mL [7–7.9]) (p < 0.001). MDA levels peaked in Group 4 (33.66 nmol/g [24.39–45.39]), while GSH values remained comparable between Groups 3 and 4. SOD increased significantly in Groups 2–4 (Group 4: 6.25 ng/mL [5.2–7.0]) compared to Group 1 (4.95 ng/mL [3.9–5.6]) (p < 0.001).

Conclusion

Although Nintedanib is antifibrotic in pulmonary contexts, it appears to promote penile fibrosis post-IP, likely via excessive VEGFR-2 inhibition, impairing vascular recovery and erectile function. Further studies are needed.